Quoin Pharmaceuticals Ltd ADR (QNRX) Stock Price, Quote & News

Company Profile

Quoin Pharmaceuticals, Ltd., a late stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). It also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat Netherton Syndrome; and QRX008 for the treatment of scleroderma. It has a research agreement with Queens...

Industry: Biotechnology

Sector: Healthcare

Phone: 703 980 4182

Website: quoinpharma.com

Address:

42127 Pleasant Forest Court, Ashburn, United States

ReversedRunners Apr. 23 at 7:43 PM

$HITI $EOSE $QNRX $BYND adding

0 · Reply

SK8RS Apr. 23 at 1:07 AM

$QNRX swing time

0 · Reply

Biotech_Pharma_Investor Apr. 22 at 6:38 PM

$QNRX Looking at clinical trial registries and company websites AZTR (ph1b) and Biocryst (ph1 stage) indeed seem to be the only ones actively enrolling.

1 · Reply

Biotech_Pharma_Investor Apr. 22 at 6:05 PM

$QNRX I don't get the bear thesis (1) Will be first mover in Netherton. What are the chances these whole body responses are due to the vehicles?? (2) Expansion to peeling skin syndrome (convincing POC in 1st patient) (3) Other indications (4) PRV for Netherton Yes they will probably raise during 2026. But good catalysts to help them raise Netherton just the beginning. Pipeline early stage but seriously underestimated. What am I missing??

1 · Reply